Simultaneously, venetoclax (ABT-199), a selective Bcl-2 inhibitor, had been approved for the treatment of hematologic malignancies, including acute myeloid leukemia [11, 12]. This evidence concerns the gene BCL2 and acute myeloid leukemia.